Erythropoietin polysialic - Xenetic Biosciences

Drug Profile

Erythropoietin polysialic - Xenetic Biosciences

Alternative Names: ErepoXen; Polysialic EPO; Polysialic erythropoietin; PSA-EPO; SYN-20070131RU

Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator Lipoxen Technologies; Serum Institute of India
  • Developer Serum Institute of India; SynBio; Xenetic Biosciences
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 11 Oct 2016 Interim efficacy, adverse events and pharmacokinetics data from a phase II trial in Anaemia (in patients with chronic kidney disease) released by Xenetic Biosciences
  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2015 Phase-II clinical trials in Anaemia in South Africa (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top